BMY trade ideas
$BMY to the mid-low $60s?$BMY has held up remarkably well during the market sell off. That said, I don't think that it's going to escape the downside for that much longer.
We've tested the $77-78 region multiple times and just rejected again. Seeing the price action today makes me think that it's finally time for BMY to fall lower. Once $BMY breaks $75, there's not much holding it up. I think we could see a fairly quick move down to the $60 range, at $65 which would be the first support and $61 which would be the second support.
There's a chance it falls into the $50s but I'll likely take profits in the $60s as it's rare for BMY to have such a substantial drop.
Let's see what happens over the coming days/weeks.
BMY Long Play Bristol-Myers Squibb Company (BMY) is a biopharmaceutical company that engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis.
Investments continue to flow into the healthcare industry and BMY is ripe to benefit. Adding it long
BMY going South with a breeze. BMYImmediate targets 61, 59, 56, 53. Invalidation at 79.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
BMY Long Term LongHealthy pipeline.
Sitting at 3.32% yield and 8.62 P/E (norm is 18.65 and 5Y norm is 11.17) with earnings growth rate approx. 6.18% since 2000 but has increased to 15-16% if you look at the 10Y and 5Y norms.
Estimates are for about 4-6% the next 2 years.
A+ Credit Rating
48LT Debt to Cap
PT $96 by 2023 using a 7% earnings growth rate and 12 P/E
HUGE saucer pattern -- technically.
Bristol Myers going South. BMYImmediate targets 61,59, 56, 53. Invalidation at 79.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
BMY to break out in the next several yearsBMY is presently in a wedge. Though a breakdown is certainly possible over the next decade, what are reasonable breakout levels to watch? This chart with Fib levels induced by the move from all-time lows to all-time highs gives some clues.
Approximately $75 is first up, then approximately $120.
$BMY bouncing off long-term support (4/5)Conviction: 4/5
might be better to buy when the stock goes over 1998 resistance
General Thesis
bouncing off of multi-cycle support (since 1974)
Weekly RSI showing sliiight bullish divergence
Growth
Margins quite low compared to own history
low growth
Value
very cheap
Fundamentals
low debt/asset ratio and plenty of cash to deal with short term debts
Potential Risks
expensive market...
long-term resistance around 76 since 1998